VaxGen Receives $11M Consolation Prize
Under the terms of the contract, which was awarded in 2004, VaxGen was supposed to provide 75 million doses of a modern anthrax vaccine for civilian biodefense. However, the company failed to demonstrate that its vaccine maintained potency, and it also failed to meet certain deadlines.
As a result, the...
To view the full article, register now.